**Interim group results for the six months ended 28 February 2005**

### Condensed Consolidated Income Statement

<table>
<thead>
<tr>
<th>Period</th>
<th>Revenue</th>
<th>Profits before interest and taxation</th>
<th>Earnings per share (cents)</th>
<th>Cash effects of operating activities</th>
</tr>
</thead>
<tbody>
<tr>
<td>2005</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>$8 997</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Notes
- [33x1062] Profit before interest and taxation
- [33x592] Undiluted earnings per share
- [33x112] (114 184)
- [33x156] Operating expenditure
- [33x258] [28 February 2004]

### Condensed Consolidated Balance Sheet

#### Notes
- [33x1062] Profit before interest and taxation
- [33x592] Undiluted earnings per share
- [33x112] (114 184)
- [33x156] Operating expenditure
- [33x258] [28 February 2004]

### Financial performance

The group increased turnover from continuing operations by 24.6% to R4.4 billion in the six-month period, with the most significant growth coming from 24.2% and attributable distributable income, increasing by 34.1% including sales to group companies. The year-on-year comparison of the group's operating profit has been strongly impacted by the loss on the disposal of the new Clicks' single exit pricing, this was largely neutralised by increased sales volumes. The group's operating profit declined 23.7% owing to increased expenses and reduced margins. The pharmacy division also achieved a strong increase in earnings.

### Commentaries

#### Financial performance

The group increased turnover from continuing operations by 24.6% to R4.4 billion in the six-month period, with the most significant growth coming from 24.2% and attributable distributable income, increasing by 34.1% including sales to group companies. The year-on-year comparison of the group's operating profit has been strongly impacted by the loss on the disposal of the single exit pricing, this was largely neutralised by increased sales volumes. The group's operating profit declined 23.7% owing to increased expenses and reduced margins. The pharmacy division also achieved a strong increase in earnings.

### Supplemental Information

#### Financial performance

The group increased turnover from continuing operations by 24.6% to R4.4 billion in the six-month period, with the most significant growth coming from 24.2% and attributable distributable income, increasing by 34.1% including sales to group companies. The year-on-year comparison of the group's operating profit has been strongly impacted by the loss on the disposal of the single exit pricing, this was largely neutralised by increased sales volumes. The group's operating profit declined 23.7% owing to increased expenses and reduced margins. The pharmacy division also achieved a strong increase in earnings.

### Condensed Consolidated Changes in Equity

#### Notes
- [33x1062] Profit before interest and taxation
- [33x592] Undiluted earnings per share
- [33x112] (114 184)
- [33x156] Operating expenditure
- [33x258] [28 February 2004]